Suppr超能文献

[60例霍奇金淋巴瘤化疗与放疗的疗效]

[Effectiveness of chemotherapy and radiotherapy in 60 cases of Hodgkin's lymphoma].

作者信息

Yong W B, Wang H, Zhu X M

机构信息

Beijing Institute for Cancer Research.

出版信息

Zhonghua Nei Ke Za Zhi. 1993 Feb;32(2):91-3.

PMID:7691489
Abstract

60 cases of Hodgkin's lymphoma were treated with combined chemotherapy and radiotherapy. 35 cases (58.3%) achieved complete remission (CR) and 25 cases (41.7%) partial remission (PR). Five and ten-year survival rates were 55.2% and 47.7% for the entire group. The five and ten-year survival rates were better for patients with stage I (100% and 100%), stage II (69.1% and 62.1%), and stage III (71.5% and 59.6%) than for patients with stage IV (16.2% and 16.2%), better for CR patients (89.4% and 81.3%) than for PR patients (10.1% and 5%) and better for patients with lymphocyte predominating type (75% and 50%) and nodular sclerosis type (74.5% and 65.2%) than for patients with mixed cellularity type (37.7% and 37.7%) and lymphocyte depleted type (0% and 0%). The results show that the stage and histologic type of the disease, the CR rate and the age of the patients had significant effect on the survival of Hodgkin's lymphoma. In order to improve the prognosis, it is important to make diagnosis early and to achieve CR.

摘要

60例霍奇金淋巴瘤患者接受了联合化疗和放疗。35例(58.3%)达到完全缓解(CR),25例(41.7%)部分缓解(PR)。全组患者的5年和10年生存率分别为55.2%和47.7%。I期(100%和100%)、II期(69.1%和62.1%)和III期(71.5%和59.6%)患者的5年和10年生存率高于IV期患者(16.2%和16.2%),CR患者(89.4%和81.3%)的生存率高于PR患者(10.1%和5%),淋巴细胞为主型(75%和50%)和结节硬化型(74.5%和65.2%)患者的生存率高于混合细胞型(37.7%和37.7%)和淋巴细胞消减型(0%和0%)患者。结果表明,疾病的分期、组织学类型、CR率和患者年龄对霍奇金淋巴瘤的生存有显著影响。为改善预后,早期诊断并实现CR很重要。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验